High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
SCHD just delivered a return most dividend investors spend a decade waiting for, and that success created a problem nobody predicted. Whether fresh money belongs in the fund right now depends on a tradeoff that long-term holders never had to face.
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical
BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.
Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. The timing of the setback could not be more vi
Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation buy on a revenue base this thin?
Moderna just handed back 7% of its staggering year-to-date run in a single session, and the question rattling traders is whether this is a routine exhale or the beginning of a painful unwind for latecomers.
Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a...
SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.7% and th
Moderna's mRNA cancer vaccine sent shares on one of biotech's wildest two-day rides in years, but the brutal Thursday reversal raises a question investors now have to answer: does the science justify what the market priced in?
RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.
A historic one-session rally in a cancer vaccine stock is already unwinding, and Wall Street analysts disagree sharply on whether the reversal reflects a trade gone cold or an opportunity that the market is mispricing.
RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.
Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win. mRNA Has ‘Tremendous’ Potential “Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases,” Musk said in a post on X. “Artificial RNA essentially makes curing diseases a software probl
By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh
Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
The pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
